Today: 14 June 2026
Browse Category

NASDAQ:MDIN 22 May 2026

Medline’s $2.7 billion stock sale puts demand for IPO favorite on the line

Medline’s $2.7 billion stock sale puts demand for IPO favorite on the line

Medline shareholders priced a 72.6 million-share secondary offering at $37 each, raising $2.68 billion, with the company receiving no proceeds. Shares traded near $37 late Friday, above the $29 IPO price but below December’s peak. The offering was upsized from 60 million shares, with underwriters holding an option for more. Major sellers include affiliates of Blackstone, Hellman & Friedman, and Abu Dhabi Investment Authority.
22 May 2026
·

Stock Market Today

  • Northern Dynasty Minerals Shares Surge 6.8% as DOJ Supports EPA Pebble Mine Veto
    June 14, 2026, 12:23 AM EDT. Northern Dynasty Minerals (TSX:NDM) shares rose 6.8% following the U.S. Department of Justice's formal backing of the Environmental Protection Agency's (EPA) veto against the Pebble Project mine development. This reinforces federal opposition, shifting the company's outlook toward prolonged legal battles rather than permitting progress. The DOJ's defense of the EPA's veto increases uncertainty over project timelines and future funding. Investors face a binary risk profile, given the project's current zero revenue and high valuation multiples. Market reactions underscore the DOJ's legal stance as a key near-term driver, while fair value estimates for the stock range widely from US$0.24 to US$2.40, reflecting varied investor risk tolerance. The development highlights significant legal and financial risks for Northern Dynasty Minerals' investment case.

Latest articles

Kraft Heinz Shares Rally for Six Days—Is KHC a Buy Now?

Kraft Heinz Shares Rally for Six Days—Is KHC a Buy Now?

14 June 2026
Kraft Heinz closed up 0.70% at $24.39, outpacing the S&P 500, as investors weighed its 6.6% dividend yield against falling organic sales, lower adjusted earnings, and cautious analyst targets; the next earnings update is seen as the key test for whether $600 million in marketing and R&D can revive growth and support the stock’s rebound.
Go toTop